DR. HOWARD DITTRICH, M.D
Osteopathic Medicine at Arbor Dr, San Diego, CA
License number
California A34166
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California A34166
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
2
200 W Arbor Dr, San Diego, CA 92103
9500 Gilman Dr, La Jolla, CA 92093
9500 Gilman Dr, La Jolla, CA 92093
Phone
(858) 657-8530
Personal information
See more information about HOWARD DITTRICH at radaris.comName
Address
Phone
644 Arenas St, La Jolla, CA 92037
1020 Evergreen St, San Diego, CA 92106
10485 Livewood Way, San Diego, CA 92131
Organization information
See more information about HOWARD DITTRICH at bizstanding.comHoward Dittrich MD
9350 Campus Pt Dr, La Jolla, CA 92037
Industry:
Internist
Phone:
(858) 657-8530 (Phone)
Howard Clemens Dittrich
Professional information
Consultant At Prism Biolab Corporation
Position:
Adjunct Professor of Medicine, Chair Cardiovascular Center Board of Directors at U of Iowa Carver College of Medicine, Chief Medical Officer at Sorbent Therapeutics, Inc, Consultant at PRISM Biolab Corporation, CMO at ChanRx Corp, Consultant at Celladon Corporation
Location:
Greater San Diego Area
Industry:
Pharmaceuticals
Work:
U of Iowa Carver College of Medicine
- Iowa City, Iowa since Jul 2012
-
Adjunct Professor of Medicine, Chair Cardiovascular Center Board of Directors
Sorbent Therapeutics, Inc
- Sunnyvale, CA since Jan 2012
-
Chief Medical Officer
PRISM Biolab Corporation
- Yokohama, Kanagawa, Japan since 2012
-
Consultant
ChanRx Corp
- Cleveland, Ohio since Nov 2011
-
CMO
Celladon Corporation
- La Jolla, CA since May 2008
-
Consultant
Sequel Pharmaceuticals Inc
2007 - Jun 2011
-
CMO
UCSD Medical Center
1996 - Jun 2011
-
Retired Professor of Medicine
NovaCardia
2003 - 2007
-
CMO
Alliance Pharmaceuticals
2000 - 2002
-
CMO
Education:
University of Iowa Roy J. and Lucille A. Carver College of Medicine 1974 - 1978
MD, Medicine Amana High School
high school diploma UCSD School of Medicine
University of Iowa
MD, Medicine Amana High School
high school diploma UCSD School of Medicine
University of Iowa
Analysis Of Ultrasound Images In The Presence Of Contrast Agent
US Patent:
5776063, Jul 7, 1998
Filed:
Sep 30, 1996
Appl. No.:
8/723898
Inventors:
Howard Dittrich - San Diego CA
Harold Levene - San Diego CA
Eric Mjolsness - Encinitas CA
Harold Levene - San Diego CA
Eric Mjolsness - Encinitas CA
Assignee:
Molecular Biosystems, Inc. - San Diego CA
International Classification:
A61B 500, A61B 800
US Classification:
600408
Abstract:
A method and apparatus for directly identifying and characterizing input data derived from regions of interest in ultrasound images of organs in the presence of attenuation from interposed contrast agent, for the purpose of diagnosing abnormalities. The input data is classified into one of a number of classes depending upon the characteristics of that data, in order to distinguish normal conditions from abnormal conditions. The invention is based on the recognition that significant information relating to the health of tissue exists in regions of interest in ultrasound images in the presence of attenuation from interposed contrast agent. This information is in the form of backscatter speckle patterns that have "texture" characteristics that are distinguishable in healthy versus diseased tissue. The invention classifies such patterns as probably normal or abnormal by means of an analysis system that may include a neural network system. The preferred embodiment of the present invention includes: (1) a data acquisition system for acquiring ultrasound image data indicative of a region of interest in the presence of attenuation from interposed contrast agent; (2) an optional signal conditioning stage to remove signals (e. g.
Method For Shortening Hospital Stay In Patients With Congestive Heart Failure And Acute Fluid Overload
US Patent:
2007029, Dec 20, 2007
Filed:
Jun 15, 2007
Appl. No.:
11/763993
Inventors:
Howard Dittrich - San Diego CA, US
Brian Farmer - San Diego CA, US
Randy Woods - Rancho Santa Fe CA, US
Brian Farmer - San Diego CA, US
Randy Woods - Rancho Santa Fe CA, US
International Classification:
A61K 31/58, A61K 31/549, A61K 31/4747, A61K 31/522
US Classification:
514172000, 514223500, 514278000, 514263320
Abstract:
Methods of treating patients with acute fluid overload comprising administering diuretic therapy and an amount of KW-3902, a pharmaceutically acceptable salt, ester, amide, metabolite, or prodrug thereof, effective to accelerate removal of excess fluid from the patient in comparison to diuretic therapy alone. Methods of improving the treatment time to achieve adequate diuresis in an individual experiencing acute fluid overload comprising administering to said individual a diuretic and a therapeutically effective amount of KW-3902 or a pharmaceutically acceptable salt, ester, amide, metabolite, or prodrug thereof.
Cmo At Sequel Pharmaceuticals
Position:
CMO at Sequel Pharmaceuticals
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
Sequel Pharmaceuticals
since Sep 2007
-
CMO
Education:
University of Iowa Roy J. and Lucille A. Carver College of Medicine 1974 - 1978
Howard C Dittrich, San Diego CA
Specialties:
Internist
Address:
200 W Arbor Dr, San Diego, CA 92103
Method Of Treatment Of Cardiac And/Or Renal Failure Using A Calcium Channel Blocker And An Angiotensin Converting Enzyme Inhibitor Or An Angiotensin Ii Receptor Blocker
US Patent:
2006005, Mar 16, 2006
Filed:
Aug 23, 2005
Appl. No.:
11/209463
Inventors:
Howard Dittrich - San Diego CA, US
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
International Classification:
A61K 31/455, A61K 31/4439
US Classification:
514338000, 514355000
Abstract:
Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.
Methods Of Treating Heart Failure And Renal Dysfunction In Individuals With An Adenosine A1 Receptor Antagonist
US Patent:
2009019, Aug 6, 2009
Filed:
Mar 28, 2008
Appl. No.:
12/058129
Inventors:
Howard Dittrich - San Diego CA, US
International Classification:
A61K 31/522, A61P 13/12
US Classification:
51426334
Abstract:
Provided herein are methods of improving, maintaining and restoring renal function, treating heart failure, treating subjects with acute fluid overload, and slowing or reversing an existing or developing renal impairment in subjects with BNP levels of at least 400 pg/mL and/or NT-proBNP levels of at least about 1500 pg/mL by administering a therapeutically effective amount of an AARA to the subject.
Method Of Improved Diuresis In Individuals With Impaired Renal Function
US Patent:
2006003, Feb 16, 2006
Filed:
Oct 11, 2005
Appl. No.:
11/248905
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Howard Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
Lauren Otsuki - San Diego CA, US
Howard Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
International Classification:
A61K 31/549, A61K 31/522
US Classification:
514263320, 514223500
Abstract:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.
Method Of Treatment Of Disease Using An Adenosine A1 Receptor Antagonist And An Aldosterone Inhibitor
US Patent:
2009025, Oct 8, 2009
Filed:
Jun 16, 2009
Appl. No.:
12/485797
Inventors:
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Howard C. Dittrich - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Howard C. Dittrich - San Diego CA, US
International Classification:
A61K 31/585, A61K 31/522, A61P 9/00, A61P 13/12, A61P 9/04, A61P 9/12, A61P 9/10
US Classification:
514171, 514173, 51426323, 51426324
Abstract:
Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine Areceptor antagonist (AARA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.
Method Of Improved Diuresis In Individuals With Impaired Renal Function
US Patent:
2006029, Dec 28, 2006
Filed:
Jun 16, 2006
Appl. No.:
11/454665
Inventors:
Howard Dittrich - San Diego CA, US
Brian Farmer - San Diego CA, US
Randy Woods - Rancho Santa Fe CA, US
Brian Farmer - San Diego CA, US
Randy Woods - Rancho Santa Fe CA, US
International Classification:
A61K 31/549, A61K 31/522, A61K 31/4965
US Classification:
514223500, 514263340, 514263320, 514255050
Abstract:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.